167 related articles for article (PubMed ID: 19306385)
1. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
Newcorn JH; Donnelly C
Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
[No Abstract] [Full Text] [Related]
2. Stimulants and sudden death: what is a physician to do?
Wilens TE; Prince JB; Spencer TJ; Biederman J
Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
[TBL] [Abstract][Full Text] [Related]
3. [Medication for ADHD and the risk of cardiovascular mortality].
Kalverdijk LJ; Buitelaar JK; van der Gaag RJ
Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2283-4; author reply 2284. PubMed ID: 17078147
[No Abstract] [Full Text] [Related]
4. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
Wooltorton E
CMAJ; 2006 Jul; 175(1):29. PubMed ID: 16772535
[No Abstract] [Full Text] [Related]
5. [Attitude to questionable cadiac risks in stimulant administration].
Fegert JM; Hebebrand J;
Z Kinder Jugendpsychiatr Psychother; 2006 Jul; 34(4):295-7. PubMed ID: 16927572
[No Abstract] [Full Text] [Related]
6. ADHD drugs and cardiovascular risk.
Rappley MD; Moore JW; Dokken D
N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729375
[No Abstract] [Full Text] [Related]
7. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
Knight M
Pediatrics; 2007 Jan; 119(1):154-5. PubMed ID: 17200281
[No Abstract] [Full Text] [Related]
8. [Treatment with central nervous system stimulants. Practical guidelines].
Hvolby A; Jørgensen JI
Ugeskr Laeger; 2004 Jan; 166(3):144-8. PubMed ID: 14870640
[No Abstract] [Full Text] [Related]
9. Are stimulants overprescribed?
Perry R; Gilbert EM; Angkustsiri K
J Am Acad Child Adolesc Psychiatry; 2000 Mar; 39(3):269-70; author reply 270-1. PubMed ID: 10714041
[No Abstract] [Full Text] [Related]
10. Are stimulants overprescribed?
Diller LH
J Am Acad Child Adolesc Psychiatry; 2000 Mar; 39(3):269; author reply 270-1. PubMed ID: 10714040
[No Abstract] [Full Text] [Related]
11. Debate over warnings for ADHD stimulants.
Child Health Alert; 2006 Apr; 24():1. PubMed ID: 16673500
[No Abstract] [Full Text] [Related]
12. ADHD drugs and cardiovascular risk.
Nissen SE
N Engl J Med; 2006 Apr; 354(14):1445-8. PubMed ID: 16549404
[No Abstract] [Full Text] [Related]
13. [Treatment with central nervous system stimulants].
Zlotnik G
Ugeskr Laeger; 2004 Mar; 166(10):925; author reply 925. PubMed ID: 15045741
[No Abstract] [Full Text] [Related]
14. US senator alleges FDA tried to prevent Adderall XR withdrawal in Canada.
Eggertson L
CMAJ; 2005 Mar; 172(7):865. PubMed ID: 15758187
[No Abstract] [Full Text] [Related]
15. Hyperactivity really IS common...and a new warning about treatment.
Child Health Alert; 2005 Nov; 23():3. PubMed ID: 16416539
[No Abstract] [Full Text] [Related]
16. Authentic faux diamonds and attention deficit disorder.
Anijar K; Gabbard D
Am J Bioeth; 2005; 5(3):67-70. PubMed ID: 16006371
[No Abstract] [Full Text] [Related]
17. Stimulant medications and attention deficit-hyperactivity disorder.
Cohen AL; Jhung MA; Budnitz DS
N Engl J Med; 2006 May; 354(21):2294-5. PubMed ID: 16723627
[No Abstract] [Full Text] [Related]
18. To box OR NOT TO box.
Newstadt M
J Ky Med Assoc; 2006 Aug; 104(8):344-5. PubMed ID: 16939037
[No Abstract] [Full Text] [Related]
19. Evaluation of attention deficit hyperactivity disorder.
Frazier JP; Barratt MS; Smith KC
J Pediatr Health Care; 1999; 13(5):250-3. PubMed ID: 10776202
[No Abstract] [Full Text] [Related]
20. Compliance with FDA recommendations for pemoline.
Sarkis EH
J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):383; author reply 383. PubMed ID: 12649623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
